Promino closes $403K second tranche to fund nutrition growth
What's the deal? Promino Nutritional SciencesDealroom has a profile for this one. Try Dealroom →, a Canadian performance nutrition company focused on clinically validated amino acid formulations, has closed the second tranche of its private placement. The company issued 13,437,000 units at C$0.03 each, raising gross proceeds of C$403,110.
Each unit comprises one share and half a share purchase warrant, with each whole warrant exercisable at C$0.06 for one year from issuance. Promino paid C$11,340 in cash finder's fees and issued 378,000 finder's warrants on the same terms.
The company trades on the Canadian Securities Exchange under the ticker MUSL.
Why now? This is the latest step in a fundraising effort Promino has been running since March 2026, with prior announcements on March 13, April 22, and May 5. The company says it needs the capital to accelerate growth through inventory investments and to fund general corporate purposes.
What could go wrong? All securities from the second tranche carry a four-month hold period under applicable securities laws, limiting near-term liquidity for investors. At C$0.03 per unit, the company is raising capital at a very low price point — a sign of its micro-cap status and the dilution risk shareholders face.
The securities have not been registered under US securities laws and cannot be offered or sold in the US without an exemption.
The signal: Promino's repeated micro-tranches at C$0.03 per unit underscore the funding constraints facing early-growth nutrition companies without strong institutional backing. Dealroom classifies the company as "early growth," yet its reliance on small, staggered private placements at rock-bottom prices suggests it has yet to attract the kind of capital that would signal meaningful commercial traction in the competitive performance nutrition market.
Read more: wallstreet-online.de
